Table 1 Patient, tumor and treatment features
From: Interstitial high-dose rate brachytherapy as boost for anal canal cancer
Items | N/Median | Interval/% |
|---|---|---|
Age (years) | 60 | [34 - 83] |
Sex ratio (F/M) | 3 | |
VIH Positive | 2 | 7.1 |
Tumor stage | ||
T1 | 5 | 17.9 |
T2 | 20 | 71.4 |
T3 | 2 | 7.1 |
T4 | 1 | 3.6 |
Lymph node status | ||
N0 | 25 | 89.3 |
N1 | 2 | 7.1 |
N2 | 1 | 3.6 |
Histologic type | ||
SCC | 25 | 89.3 |
ADC | 3 | 10.7 |
EBRT | ||
Chemotherapy | 20 | 71.4 |
Inguinal irradiation | 20 | 71.4 |
Total dose (Gy) | 45 | [43.2 - 52] |
HDR BT | ||
d/f (Gy) | 4 | [3 - 5] |
# of fractions | 3 | [2 - 6] |
Total dose (Gy) | 12 | [10 - 15] |
# of needles | 4 | [4 - 7] |
TI EBRT/BT (days) | 20 | [4 - 63] |
OTT (days) | 63 | [38 - 74] |